Bohling v. Pharmacia Corp.

156 F. Supp. 2d 1010, 2001 U.S. Dist. LEXIS 13798, 2001 WL 1028391
CourtDistrict Court, N.D. Illinois
DecidedSeptember 5, 2001
Docket00 C 5207
StatusPublished
Cited by2 cases

This text of 156 F. Supp. 2d 1010 (Bohling v. Pharmacia Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bohling v. Pharmacia Corp., 156 F. Supp. 2d 1010, 2001 U.S. Dist. LEXIS 13798, 2001 WL 1028391 (N.D. Ill. 2001).

Opinion

MEMORANDUM OPINION AND ORDER

MORTON DENLOW, United States Magistrate Judge.

This case presents the issue of whether a release executed by plaintiff in connection with his severance from his former employer bars him from suing his former employer for breach of contract and promissory estoppel. The answer is yes.

Plaintiff Richard Bohling (“Plaintiff’/ “Bohling”) filed a two-count first amended complaint against his former employer, Pharmacia Corporation f/k/a Monsanto Company (“Defendant”/“Monsanto”), arising out of his departure from Monsanto pursuant to a corporate restructuring. Count I alleges breach of contract in violation of a written separation agreement. Count II alleges an alternative claim for promissory estoppel.

The matter comes before this Court on cross-motions for summary judgment on both counts. Plaintiff moves for summary judgment contending Defendant breached the separation agreement because it failed to eliminate his former position and alternatively, if no enforceable contract exists, that he is entitled to judgment as a matter of law on his claim for promissory estop-pel.

Defendant moves for summary judgment contending Plaintiff is barred from pursuing his claims because the separation agreement includes a binding release and because the written agreement bars his claim for promissory estoppel. For the reasons set forth in this opinion, summary judgment is granted in favor of the Defendant and against the Plaintiff on both counts.

I. BACKGROUND FACTS

A. The Parties

Bohling is a resident of Rochelle, Illinois and is a former employee of Monsanto. (Def.Resp-¶¶ 1, 12). Monsanto is a Delaware corporation engaged in the seed production business and is based in St. Louis, Missouri. (Def.Resp-¶ 2). Bohling joined Pfizer Genetics in 1978 as the Manager of Production Research and was promoted in 1980 to Manager of Agronomic Services. (Def.Resp.f 8). In 1982 Pfizer Genetics merged with DeKalb Ag Research and Bohling relocated to DeKalb, Illinois. (PI. Stat-¶ 9). The new company was called DeKalb Pfizer-Genetics and later the company changed names twice. Monsanto acquired Bohling’s previous employer, De-Kalb Genetic Corporation (“DeKalb”), in November 1998. (Def.Resp-¶ 12). Bohl- *1012 ing was employed at Monsanto’s DeKalb, Illinois facility from the time of Monsanto’s acquisition of the DeKalb plant until his termination on November 30, 1999. (Def. Resp. ¶¶ 12 and 19). At the time Monsanto purchased DeKalb, Bohling was employed as Manager, Agronomic Information, a position he had held since mid-1997. (Def.Resp-¶ 11). In addition, Monsanto completed the acquisition of another seed company, Asgrow, in February 1997. (PL Resp-¶ 12).

B. Monsanto Restructures Company

After purchasing DeKalb, Monsanto decided to restructure its departments. (PI. Resp-¶ 13). Monsanto’s reorganization called for the integration of three companies: Monsanto, DeKalb and Asgrow, as well as the consolidation of the technical and agronomic services group of each company into a single Technology Development Department. (PLResp-¶ 14). Various positions were eliminated to achieve integration.(Pl.Resp J 15). For those employees whose positions were eliminated, Monsanto offered them a severance package. (PLResp-¶ 17).

C. The Separation Agreement

The Monsanto reorganization contemplated the physical consolidation of the entire Technology Development Department in St. Louis (Pl.RespJ 20). Dale Sorenson, Co-Lead in Technology Development during integration of the companies, desired to keep the entire department together. (Pl.RespJ 21). Bohling’s supervisor, Dale Sorenson (“Sorenson”), informed Bohling in September 1999 that his department was relocating to St. Louis and that Bohling could either relocate to St. Louis or accept a severance package. (Bohling Dep. at p. 30). Bohling declined to relocate and chose to accept the severance package. (Def.Ex. 5).

In September 1999 and October 1999, Human Resources Generalist Donna Turner met with Plaintiff. (Def.RespJ 19). Turner met with Bohling in September to provide him with basic information regarding the Separation Program. (Turner Aff. ¶ 10). She met with him in October to provide him with his own individual summary of separation benefits. (Def. Ex. 6 and Turner Aff. ¶ 15). Severance pay was determined by calculating two weeks salary for every year of service (with a maximum of one year’s salary). (Turner Dep. at p. 29). Bohling had 21 years of service and received 42 weeks of severance. (Def.RespJ 19, Def.Ex. 6).

In November 1999 Bohling received a document entitled DeKalb Genetics Corporation Separation Program dated November 1, 1999 (“Separation Agreement”) for his review. (Def.RespJ 20). The Separation Agreement was executed by Bohling on December 10, 1999 and returned to Monsanto. (Def.Ex. 5). The Separation Agreement asks Bohling to “carefully review the Agreement and Release below and sign it to indicate your acknowledgment, agreement and acceptance of these terms.” (Pl.Ex. 5, p. 1). Bohling read the Separation Agreement and understood its terms. (Bohling Dep. at p. 82). By signing it, Bohling acknowledged he had reasonable time to consider the meaning and effect of the release and had the opportunity to and had been advised to consult an attorney. (Turner Aff. ¶ 16, Def. Ex. 5, p. 1). Bohling chose not to speak with an attorney. (Bohling Dep. at p. 82).

The Separation Agreement contained a release provision which provided in pertinent part that Bohling:

release[s], remise[s] and forever discharge[s] DeKalb Genetics Corporation hereinafter referred to as “DeKalb” and its assigns (collectively hereinafter referred to as “Monsanto”) from any and all rights, claims or other causes of action that I [Bohling] may have against *1013 them relating to or arising out of my employment and the termination of that employment, including but not limited to... claims for breach of express or implied contract. (Def.Ex. 5, pp. 1-2).

Pursuant to the Separation Agreement, Bohling was paid the following amounts: 1) severance pay in the amount of $75,381.05; 2) accrued vacation pay in the amount of $8,602.84; and 3) educational/financial planning assistance in the amount of $3,000. (Turner Aff. ¶ 18).

D. The Reorganization of Monsanto

After Bohling signed the Separation Agreement and left the company, he learned in January or February 2000 that others within his former department at DeKalb had not relocated to St. Louis. (Bohling Dep. at 35, 38). Monsanto decided not to relocate the TIS positions to St. Louis after a directive to company management, during the second week of January 2000, to reduce its operating budgets for the year 2000 by 15%. (Sorenson Aff. ¶¶ 25-27).

Bohling is currently employed at Farm-Page.com in Waterman, Illinois, an internet company which provides agricultural information to farmers. Bohling’s position is Director of Agronomy. (Pl.Resp.1HI 26-27).

II. SUMMARY JUDGMENT STANDARD

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
156 F. Supp. 2d 1010, 2001 U.S. Dist. LEXIS 13798, 2001 WL 1028391, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bohling-v-pharmacia-corp-ilnd-2001.